IOL Chemicals Announces Interim Dividend of ₹1/Share; Record Date Feb 17
IOL Chemicals and Pharmaceuticals Limited has declared an interim dividend of ₹1 per share for FY 2025-26. The record date for this dividend is February 17, 2026. The company will deduct TDS as per income tax regulations.
An interim dividend of ₹1 per share is a positive development, but its impact on the stock price might be moderate as it is a routine distribution rather than a significant increase in payout or a special dividend.
The announcement of a dividend is a positive signal to shareholders, indicating the company's profitability and willingness to distribute profits.
IOL Chemicals and Pharmaceuticals Limited (IOLCP) has announced an interim dividend of ₹1 per equity share (50%) for the financial year 2025-26. The record date for determining the shareholders' entitlement to this dividend has been fixed as Tuesday, February 17, 2026.
The Board of Directors approved this interim dividend at their meeting held on February 11, 2026. Shareholders should be aware that the dividend income is taxable, and the company will deduct tax at source (TDS) where applicable, in compliance with the Income Tax Act, 1961. Shareholders who have not submitted necessary documents for TDS non-deduction are urged to do so with the Registrar and Transfer Agent (RTA) before the record date. Additionally, shareholders holding shares in physical form with un-updated bank or KYC details are requested to update them immediately with the RTA to avoid dividend withholding, as per SEBI Master Circular dated May 17, 2023.
The company has published this information in the Financial Express (English) and Punjabi Jagran (Punjabi) newspapers. Details regarding the record date are also available on the company's website (www.iolcp.com) and the websites of the stock exchanges (www.bseindia.com and www.nseindia.com).
What to do with a filing like this
IOL Chemicals and Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under dividend. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by IOL Chemicals and Pharmaceuticals Limited. Read the original for the full detail.